TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14657064
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist strategy (CAS) - verapamil sustained release
Study: 14657064
Drug: Non-calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-calcium antagonist strategy (NCAS) - atenolol
Study: 11049918
Drug: Droperidol (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.625 mg IV)
Study: 11049918
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 mg IV)
Study: 11049918
Drug: Promethazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (12.5 mg IV)
Study: 8713784
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% infusion (n = 5)
Study: 8713784
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% infusion (n = 5)
Study: 1569339
Drug: Low-dose amphotericin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amphotericin B (serum concentrations of 0.2-0.4 microgram/ml)
Study: 1569339
Drug: Low-dose amphotericin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amphotericin B
Study: 29669617
Drug: Modified mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified mindfulness-based cognitive therapy (MBCT) course, comprising eight weekly 2-hour sessions with homework (mindfulness practice) between sessions.
Study: 20420997
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination in deltoid muscle
Study: 20420997
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination in vastus lateralis
Study: 18524727
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg/day)
Study: 18524727
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg/day)
Study: 8160602
Drug: Amiodarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (400 mg/day)
Study: 6407453
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg/day)
Study: 18524727
Drug: No anti-arrhythmic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-arrhythmic drugs (Control Group)
Study: 10608204
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg and chlorpheniramine maleate (CPM) 20 mg i.m.
Study: 10608204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 20 mg CPM i.m. alone
Study: 1812425
Drug: Outer membrane
Normalized name: Outer membrane protein 3B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer membrane vesicle vaccine
Study: 7023791
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of aluminum hydroxide gel (fasting)
Study: 7023791
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml magnesium hydroxide suspension (fasting)
Study: 7023791
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of aluminum hydroxide gel (fed)
Study: 7023791
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of aluminum hydroxide/magnesium hydroxide mixture (fed)
Study: 7023791
Drug: Fasted, no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted, no antacid
Study: 7023791
Drug: Fed, no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed, no antacid
Study: 28103623
Drug: Excess fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excess fatty acid (24hFA) treatment
Study: 28103623
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment in vivo
Study: 26374702
Drug: subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous interferon (IFN) β‐1a
Study: 21632446
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) 50,000 U weekly for 8 doses, then 10,000 U weekly
Study: 20027096
Drug: Postoperative analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesics
Study: 11597802
Drug: Oral sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sucralfate (3 g suspension, twice a day during radiotherapy)
Study: 11597802
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day during radiotherapy)
Study: 11597802
Drug: Oral sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sucralfate
Study: 9834047
Drug: Anticonvulsant drugs
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant drugs (specific drugs not mentioned)
Study: 8003559
Drug: Thiotepa 450‐750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa 450‐750 mg/m2, busulfan 10 or 12 mg/kg, and cyclophosphamide 120 or 150 mg/kg
Study: 8003559
Drug: Higher busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Higher busulfan dose
Study: 8003559
Drug: Ten or
Normalized name: Egaten Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten or more previous cycles of chemotherapy
Study: 2589355
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin and azlocillin
Study: 913868
Drug: Delta‐Butazolidin (phenylbutazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta‐Butazolidin (phenylbutazone 50 mg + prednisone 1.25 mg)
Study: 913868
Drug: Prednisone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1.25 mg
Study: 27471840
Drug: Prophylactic augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic augmentation with retro-muscular lightweight polypropylene mesh
Study: 25988261
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1500 mg quercetin
Study: 25988261
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of 1500 mg quercetin daily for 1 week
Study: 25988261
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of midazolam
Study: 19500787
Drug: 7-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day low-dose omeprazole infusion (3.3 mg/h)
Study: 19500787
Drug: 3-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day high-dose omeprazole infusion (8 mg/h)
Study: 19500787
Drug: 7-day low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day low-dose omeprazole infusion
Study: 16514327
Drug: Lidocaine 5
Normalized name: lidocaine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 5 mg/kg/h
Study: 16514327
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg/kg/h
Study: 16514327
Drug: Lidocaine 3
Normalized name: Lidocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 3 mg/kg/h
Study: 11085201
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 to 300 mg/day for 6 to 10 weeks
Study: 11085201
Drug: Fluvoxamine ≤300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine ≤300 mg/day for 6 to 8 weeks
Study: 11085201
Drug: Fluvoxamine ≤300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine ≤300 mg/day for ≥8 weeks
Study: 8397881
Drug: Alcohol subjects
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol subjects received sufficient alcohol to raise their blood alcohol level to .07 mg %
Study: 3453187
Drug: Diuretics (mainly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (mainly chlorthalidone)
Study: 29392743
Drug: PPD 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPD 1% pet. (6 mg)
Study: 29392743
Drug: PPD 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPD 0.3% pet. (20 mg)
Study: 29392743
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (PPD 1% and PPD 0.3%)
Study: 26866638
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (MED; n = 50)
Study: 26866638
Drug: Supportive-expressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive therapy (SET; n = 49)
Study: 26866638
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill (PBO; n = 50)
Study: 24176534
Drug: Supportive-expressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive therapy (SET)
Study: 26866638
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (MED)
Study: 25448672
Drug: IBPB associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBPB associated with Intravenous‐inhalation combined anesthesia (group NB)
Study: 25448672
Drug: Intravenous‐inhalation combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous‐inhalation combined anesthesia (group CI)
Study: 16451305
Drug: Chemical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical agents incorporated in dentifrice or mouth rinse formulations
Study: 10696890
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent glyceryl trinitrate ointment
Study: 11938776
Drug: Carvedilol (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (10mg to 40mg once daily)
Study: 11938776
Drug: Atenolol (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50mg to 100mg once daily)
Study: 9031394
Drug: Regimen-I: artemether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-I: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then placebo on the two consecutive days
Study: 9031394
Drug: Regimen-II: artemether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-II: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second day, and placebo on the third day
Study: 9031394
Drug: Regimen-III: artemether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-III: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second and third days
Study: 6347753
Drug: Flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (50 mg four times a day)
Study: 24532525
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 μg/(kg·h)⁻¹)
Study: 23422630
Drug: 6% triphala
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% triphala mouthwash, 15 ml twice a day
Study: 23422630
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine mouthwash, 15 ml twice a day
Study: 23422630
Drug: Plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water rinse, twice a day
Study: 20347681
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT) alone.
Study: 12358658
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine (2 microg x kg(‐1))
Study: 1688913
Drug: Dextran 40
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40 (500 ml per session) during 3 weeks
Study: 1688913
Drug: Placebo treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatments for 3 weeks
Study: 7387900
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily with gradual reduction over a period of 4 weeks
Study: 7387900
Drug: Carbamazepine 100
Normalized name: carbamazepine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 100 mg four times daily
Study: 24415640
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (375 mg/m2, 12 doses)
Study: 24415640
Drug: Chlorambucil (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (8 mg/m2/day, days 1-7) and Rituximab (375 mg/m2 on day 1 of cycle 3, 500 mg/m2 for cycles 4-8)
Study: 22829268
Drug: Donepezil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 3 mg/day
Study: 22829268
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day and 10 mg/day
Study: 19193706
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 (2 x 10(8) CFU/g), 200 g once daily for 2 weeks
Study: 19193706
Drug: Control yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yogurt without viable bacteria, 200 g once daily for 2 weeks
Study: 17185016
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 1mg/kg i.v. at skin closure, and at 8 and 16 hours after surgery
Study: 14975544
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg o.d. added to statin therapy (fluvastatin 40 mg)
Study: 11185669
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (statin therapy only)
Study: 14975544
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg o.d. added to statin therapy
Study: 9555595
Drug: Risperidone 8
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 8 mg once daily
Study: 9555595
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg twice daily
Study: 8200551
Drug: Adrenaline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline alone (3-10 ml of 1:100,000 adrenaline)
Study: 3312133
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg elemental zinc/day)
Study: 28557676
Drug: Intervention based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention based on the Valencia Model of Waking Hypnosis combined with Cognitive‐Behavioral Therapy
Study: 26084292
Drug: PCH (trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCH (trastuzumab and paclitaxel weekly combined with carboplatin weekly)
Study: 21943032
Drug: Docetaxel (DCT)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DCT) 20 mg/m2/week and continuous fluorouracil (5-FU) 200 mg/m2/day plus concurrent radiotherapy
Study: 21943032
Drug: Docetaxel (DCT)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DCT) 20 mg/m2/week and cisplatin (CDDP) 20 mg/m2 plus concurrent radiotherapy
Study: 19047492
Drug: Nurse-led hospice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led hospice collaborative; specific details on dosage and duration not available.
Study: 19047492
Drug: Classroom instruction;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom instruction; specific details on dosage and duration not available.
Study: 19047492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of classroom and hospice experiences; specific details on dosage and duration not available.
Study: 7600600
Drug: Denmark II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denmark II lyophilized vaccines
Study: 2223928
Drug: m-chlorophenylpiperazine (m-CPP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (m-CPP), 80 mg/day
Study: 24037083
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg orally once daily
Study: 19526744
Drug: Nidotherapy enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nidotherapy enhanced assertive treatment (up to 12 sessions)
Study: 17341178
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment therapy
Study: 16134605
Drug: S (+)
Normalized name: Guardian Paracetamol Extra Plus (+) (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S (+) ‐ismer of ibuprofen suppository (one suppository per day for 3 days)
Study: 16134605
Drug: Ibuprofen suppository
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suppository (one suppository per day for 3 days)
Study: 11512111
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg/night
Study: 11512111
Drug: Placebo 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 mg/night
Study: 9990417
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel applied immediately after washing
Study: 9990417
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel applied 20-30 min after washing
Study: 3378661
Drug: Oxaprozin 1200
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaprozin 1200 mg/day
Study: 3378661
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 100 mg/day
Study: 25505221
Drug: Strategy training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy training (n = 15, 10 sessions as adjunct to usual inpatient rehabilitation)
Study: 25505221
Drug: Reflective listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflective listening (n = 15, same dose)
Study: 6307458
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (Group G)
Study: 15008994
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TSH (rhTSH) 0.45 mg pretreatment before RAI treatment
Study: 30137527
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine (RAI) treatment
Study: 11319712
Drug: Vegetable oil-based
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil-based stanols (2.6 g sitostanol plus 1.2 g campestanol daily)
Study: 11319712
Drug: Wood-based stanols
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood-based stanols (3.7 g sitostanol plus 0.3 g campestanol daily)
Study: 3508327
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg twice daily for 2 weeks
Study: 3508327
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg twice daily for 2 weeks
Study: 3508327
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg twice daily for 2 weeks (continued from phase I)
Study: 14978133
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy (Phleum pratense, Phl P) for 2 years
Study: 14978133
Drug: Post-immunotherapy serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-immunotherapy serum
Study: 10768243
Drug: HP-eradication therapy
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-eradication therapy
Study: 8222742
Drug: Controlled-release metoclopramide
Normalized name: metoclopramide Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoclopramide ('Gastrobid Continus' tablets) 15 mg given twice daily
Study: 8222742
Drug: Normal-release metoclopramide
Normalized name: metoclopramide Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-release metoclopramide ('Maxolon') 10 mg given 4-times daily
Study: 8222742
Drug: Controlled-release metoclopramide
Normalized name: metoclopramide Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoclopramide
Study: 3544647
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine (n = 20)
Study: 20015104
Drug: S-tenatoprazole-Na 90
Normalized name: sulfacetamide sodium Ophthalmic Solution [S.O.S.S.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-tenatoprazole-Na 90 mg
Study: 20015104
Drug: S-tenatoprazole-Na 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-tenatoprazole-Na 60 mg
Study: 20015104
Drug: S-tenatoprazole-Na 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-tenatoprazole-Na 30 mg
Study: 12620168
Drug: Diuretics (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (single or combination)
Study: 1359319
Drug: FK‐224 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK‐224 (4 mg)
Study: 3925929
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (600 mg)
Study: 3925929
Drug: Carbamazepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (100 mg)
Study: 3925929
Drug: Phenytoin (1500-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (1500-2000 mg)
Study: 15367726
Drug: Carbamazepine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (800 mg)
Study: 29954374
Drug: Placebo (430
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (430 mg olive oil/day)